#Correction
Corrects an earlier piece or a popular misconception. Stays on the record.
PT-141 for male ED: what the FDA says
PT-141 is FDA-approved for low sexual desire in premenopausal women, not male erectile dysfunction, and the off-label male use has far thinner evidence.
Orzeyful isn't Ozempic for the brain
The FDA approved oveporexton for narcolepsy in August 2026. It targets the neuropeptide orexin, but the drug itself is not a peptide like semaglutide.
Browse other coverage
Latest from the blog
Adolescent GLP-1 Review: Evidence Gaps
A 2026 review finds short-term benefits from adolescent GLP-1 therapy but major gaps around growth, puberty, cognition and lifelong effects.
AGGF1 and the diabetic kidney barrier
A 2026 laboratory study links AGGF1 with glomerular barrier leakage and semaglutide-related junction changes in diabetic mice.
GLP-1s in Foot and Ankle Surgery
A 2026 review found neutral or potentially better outcomes with perioperative GLP-1 use, but all three comparative studies were retrospective.
Obesity and Facial Plastic Surgery
A 2026 review links obesity, weight loss and injectable drugs to facial-surgery questions but reports no direct patient outcomes.
PYY(3-36) and semaglutide in rat MASLD
A 48-rat MASLD study found stronger liver and mitochondrial changes with PYY(3-36) plus semaglutide, but it provides no human efficacy evidence.
Retatrutide and cognition in diabetic rats
A rat study linked retatrutide with better maze performance and lower brain inflammation, but it provides no evidence of cognitive benefit in people.